The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01627314 |
|
Recruitment Status :
Terminated
(Business decision)
First Posted : June 25, 2012
Last Update Posted : November 30, 2021
|
Sponsor:
Fate Therapeutics
Information provided by (Responsible Party):
Fate Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | March 2016 |
| Actual Study Completion Date : | May 2017 |
| Certification/Extension First Submitted : | November 24, 2021 |